Health Care [ 4/12 ] | Life Sciences Tools & Services [ 64/75 ]
NASDAQ | Common Stock
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products.
The company operates through Consumer products; Ingredients; and Pharmaceutical Segments.
It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products.
In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name.
The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers.
The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025.
Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 11, 26 | 0.03 Decreased by -69.33% | 0.02 Increased by +25.45% |
| Nov 4, 25 | 0.05 Increased by +150.00% | 0.02 Increased by +150.00% |
| Aug 6, 25 | 0.04 Increased by +154.78% | 0.02 Increased by +100.00% |
| May 7, 25 | 0.06 Increased by +700.00% | 0.02 Increased by +200.00% |
| Mar 4, 25 | 0.09 Increased by +5.90 K% | 0.02 Increased by +350.00% |
| Oct 31, 24 | 0.02 Increased by +300.00% | 0.01 Increased by +100.00% |
| Aug 7, 24 | 0.02 Increased by +152.33% | -0.02 Increased by +178.50% |
| May 8, 24 | -0.01 Increased by +66.67% | -0.02 Increased by +50.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 33.84 M Increased by +16.19% | 4.13 M Decreased by -42.44% | Increased by +12.21% Decreased by -50.46% |
| Sep 30, 25 | 33.99 M Increased by +32.86% | 4.58 M Increased by +143.77% | Increased by +13.47% Increased by +83.48% |
| Jun 30, 25 | 31.12 M Increased by +36.84% | 3.61 M Increased by +24.16 K% | Increased by +11.60% Increased by +17.68 K% |
| Mar 31, 25 | 30.48 M Increased by +37.59% | 5.06 M Increased by +1.13 K% | Increased by +16.61% Increased by +847.90% |
| Dec 31, 24 | 29.13 M Increased by +37.41% | 7.18 M Increased by +6.20 K% | Increased by +24.65% Increased by +4.48 K% |
| Sep 30, 24 | 25.58 M Increased by +31.21% | 1.88 M Increased by +295.83% | Increased by +7.34% Increased by +249.24% |
| Jun 30, 24 | 22.74 M Increased by +11.89% | -15.00 K Increased by +99.32% | Decreased by -0.07% Increased by +99.39% |
| Mar 31, 24 | 22.15 M Decreased by -1.79% | -492.00 K Increased by +74.13% | Decreased by -2.22% Increased by +73.66% |